Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-IT101 in Advanced Solid Tumors
NCT05539768Phase 1Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of HS-IT101 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), Cervical Cancer (CC) and 1 more, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Adverse Events at 12 months. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
HS-IT101
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)Cervical Cancer (CC)breast cancer
Beyond the preview
Go deeper on NCT05539768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539768.